Last edition
News about "novel therapies "
4Moving Biotech has completed patient enrollment in its global Phase 2a INFLAM MOTION trial, assessing the safety and efficacy of investigational therapy 4P004 for inflammatory knee osteoarthritis.
Novel Therapies | 05/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members